About Zevra Therapeutics, Inc.
https://zevra.comZevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States.
CEO
Neil F. McFarlane
Compensation Summary
(Year 2023)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2020-12-28 | Reverse | 1:16 |
ETFs Holding This Stock
Summary
Showing Top 3 of 65
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Canaccord Genuity
Buy
Guggenheim
Buy
HC Wainwright & Co.
Buy
JMP Securities
Market Outperform
Citizens Capital Markets
Market Outperform
Cantor Fitzgerald
Overweight
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:4.04M
Value:$37.02M
WOODLINE PARTNERS LP
Shares:3.48M
Value:$31.88M
VANGUARD GROUP INC
Shares:3.08M
Value:$28.27M
Summary
Showing Top 3 of 170
About Zevra Therapeutics, Inc.
https://zevra.comZevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $26.06M ▲ | $20.37M ▼ | $-1.41M ▼ | -5.41% ▼ | $-0.01 ▼ | $1.47M ▼ |
| Q2-2025 | $25.88M ▲ | $84.54M ▲ | $74.71M ▲ | 288.66% ▲ | $1.36 ▲ | $80.57M ▲ |
| Q1-2025 | $20.4M ▲ | $24.42M ▼ | $-3.1M ▲ | -15.19% ▲ | $-0.06 ▲ | $1.7M ▲ |
| Q4-2024 | $12.04M ▲ | $26.09M ▼ | $-35.74M ▼ | -296.76% ▲ | $-0.67 ▲ | $-16.53M ▲ |
| Q3-2024 | $3.69M | $28.7M | $-33.23M | -899.19% | $-0.69 | $-29.3M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $199.51M ▼ | $270.12M ▲ | $136.95M ▼ | $133.16M ▲ |
| Q2-2025 | $202.61M ▲ | $256.28M ▲ | $139.05M ▲ | $117.23M ▲ |
| Q1-2025 | $62.63M ▼ | $172.71M ▼ | $131.69M ▼ | $41.02M ▲ |
| Q4-2024 | $69.5M ▼ | $178.13M ▼ | $138.46M ▲ | $39.67M ▼ |
| Q3-2024 | $89.38M | $191.55M | $121.78M | $69.77M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-544K ▼ | $4.71M ▲ | $-4.58M ▼ | $6.53M ▲ | $6.73M ▼ | $4.16M ▲ |
| Q2-2025 | $74.71M ▲ | $-3.6M ▲ | $11.93M ▲ | $1.38M ▼ | $10.37M ▲ | $-3.81M ▲ |
| Q1-2025 | $-3.1M ▲ | $-8.22M ▲ | $10.54M ▲ | $1.61M ▲ | $3.56M ▲ | $-8.32M ▲ |
| Q4-2024 | $-35.74M ▼ | $-16.25M ▲ | $-5.47M ▲ | $796K ▼ | $-20.25M ▼ | $-16.25M ▲ |
| Q3-2024 | $-33.23M | $-18.14M | $-31.35M | $64.77M | $14.78M | $-18.14M |
Revenue by Products
| Product | Q1-2024 | Q2-2024 |
|---|---|---|
 License | $0 ▲ | $0 ▲ |
CEO
Neil F. McFarlane
Compensation Summary
(Year 2023)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2020-12-28 | Reverse | 1:16 |
ETFs Holding This Stock
Summary
Showing Top 3 of 65
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Canaccord Genuity
Buy
Guggenheim
Buy
HC Wainwright & Co.
Buy
JMP Securities
Market Outperform
Citizens Capital Markets
Market Outperform
Cantor Fitzgerald
Overweight
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:4.04M
Value:$37.02M
WOODLINE PARTNERS LP
Shares:3.48M
Value:$31.88M
VANGUARD GROUP INC
Shares:3.08M
Value:$28.27M
Summary
Showing Top 3 of 170